Data / Research funding / North Carolina / Baebies, Inc.
Baebies, Inc.: 14 NIH awards ($20.3M), fiscal years 2021 to 2026
Baebies, Inc. in Durham, NC is funded under 14 NIH awards ($20.3M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NZSZBQ9B84T1
- State
- North Carolina
Awards
14 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,908,098 | February 1, 2018 | March 31, 2025 | PAMULA, VAMSEE K. | reporter.nih.gov |
| A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,299,994 | November 1, 2024 | October 31, 2027 | NG, RANIER | reporter.nih.gov |
| A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,298,252 | April 10, 2023 | July 31, 2027 | PAMULA, VAMSEE K. | reporter.nih.gov |
| A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,044,830 | May 23, 2022 | May 31, 2026 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,989,830 | September 15, 2014 | March 31, 2024 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Rapid, Point-of-Care Diagnostics for Hepatitis C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,799,981 | August 12, 2022 | August 12, 2025 | UNGEWITTER, ERICA | reporter.nih.gov |
| Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,531,885 | February 11, 2021 | November 30, 2023 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,331,791 | September 21, 2021 | August 31, 2024 | NG, RAINER | reporter.nih.gov |
| A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,300,723 | December 17, 2024 | August 31, 2027 | NG, RAINER | reporter.nih.gov |
| Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $793,462 | August 16, 2018 | December 31, 2022 | AMIN, VIREN R | reporter.nih.gov |
| An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | NIH | National Heart, Lung, and Blood Institute | 2021 | $681,054 | July 1, 2019 | March 31, 2023 | ELDERBROOM, JENNIFER | reporter.nih.gov |
| A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | NIH | National Institute on Drug Abuse | 2021 | $672,757 | September 30, 2019 | July 31, 2023 | NG, RAINER | reporter.nih.gov |
| A Simple Multiplexed Platform for Self-Administered HIV and Hepatitis B Testing | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,982 | August 1, 2024 | July 31, 2028 | NG, RAINER | reporter.nih.gov |
| Development of a Rapid, Quantitative HIV-1 Assay for Viral Load Self-Monitoring | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,427 | September 1, 2025 | August 31, 2026 | NG, RAINER | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 4 | $4,599,507 | 0 | $0 |
| 2024 | 3 | $2,246,953 | 0 | $0 |
| 2023 | 4 | $2,294,104 | 0 | $0 |
| 2022 | 6 | $4,596,765 | 0 | $0 |
| 2021 | 8 | $6,514,737 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Clinical Research
- Biotechnology
- Bioengineering
- Pediatric
- Prevention
- Infectious Diseases
- Hematology
- Digestive Diseases
- Liver Disease
- Genetic Testing
- Genetics
- Perinatal Period - Conditions Originating in Perinatal Period
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.